Frontiers in Oncology (Apr 2017)

Inflammation in Prostatic Hyperplasia and Carcinoma—Basic Scientific Approach

  • Božo Krušlin,
  • Božo Krušlin,
  • Davor Tomas,
  • Davor Tomas,
  • Tihana Džombeta,
  • Tihana Džombeta,
  • Marija Milković-Periša,
  • Marija Milković-Periša,
  • Monika Ulamec,
  • Monika Ulamec

DOI
https://doi.org/10.3389/fonc.2017.00077
Journal volume & issue
Vol. 7

Abstract

Read online

Chronic inflammation is associated with both benign conditions and cancer. Likewise, inflammatory cells are quite common in benign prostatic hyperplasia (BPH) and prostatic tissue harboring cancer. Triggers that activate inflammatory pathways in the prostate remain a subject of argument and are likely to be multifactorial, some of these being bacterial antigens, different chemical irritations, and metabolic disorders. Acute and chronic inflammation in prostate leads to accumulation of immunocompetent cells, mainly T lymphocytes and macrophages, but also neutrophils, eosinophils, and mast cells, depending on the type of offending agent. Inflammatory processes activate hyperproliferative programs resulting in nodules seen in BPH, but are also important in creating suitable microenvironment for cancer growth and progression. Inflammatory cells have mostly been shown to have a protumoral effect such as tumor-associated macrophages, but some cell types such as mast cells have antitumoral effects. This review outlines the recent findings and theories supporting the role of inflammatory responses as drivers of both benign and malignant epithelial processes in the prostate gland.

Keywords